Predictive Oncology Inc. Overview
Pro stress-test →Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company offers academic and industry partners one of the industry's broadest AI-based drug discovery solutions, complemented by its wholly owned CLIA lab and GMP facilities, together with a vast biobank of more than 150,000 assay-capable heterogenous human tumor samples.
Strategic Profile
Pro stress-test →The company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. The company is changing its corporate name to Axe Compute Inc. effective December 11, 2025, reflecting a strategic pivot toward broader compute applications.
Competitive Landscape
Pro stress-test →Predictive Oncology competes in the AI-driven drug discovery and oncology research space with a differentiated platform (PEDAL) achieving 92% accuracy in tumor response prediction, supported by one of the industry's largest curated biobanks and proprietary CLIA/GMP facilities. Key competitors include PathAI (PathAI's board advisory relationship noted), traditional contract research organizations, and emerging AI drug discovery platforms.
Industry Context
Predictive Oncology Inc. operates in AI-Driven Drug Discovery and Development.
Key facts
Founded: 2002 · Headquarters: Pittsburgh, PA · Employees: 24 · Revenue: N/A · Market cap: N/A